Skip to content
Back to meeting Original
Toni Choueiri, MD· @DrChoueiri · X·· 1 day agoScore70
Body · original

Another positive Ph.III in NSCLC! #DrShunLu presents SAFFRON: osimertinib + savolitinib vs platinum/pemetrexed after osimertinib in EGFRm/MET+ disease. PFS 7.6 vs 5.4 mo (HR 0.55; p<0.001). OS 17.8 vs 12.9 mo (HR 0.68; p=0.010).

#ESMO26 #LungCancer @myESMO @OncoAlert

61 views · 1 like · 1 repost · 0 replies

Source: Toni Choueiri, MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.